Latest
industry research report on: Colorectal Cancer Therapeutics Market |
Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand,
Growth, Segmentation, Parameters, Forecasts
GBI Research, the leading business intelligence provider, has released its latest research: “Colorectal Cancer Therapeutics
in Major Developed Markets to 2020 - Increased Uptake of High Priced
Drugs to Offset the Impact of Generics”, which provides in-depth
analysis of the Colorectal Cancer (CRC) therapeutics market in the eight
major geographies of the US, Canada, the UK, France, Germany, Spain,
Italy and Japan. The report provides an estimation of the market size
for 2013, along with market forecast until 2020. It also covers disease
epidemiology, treatment algorithms, treatment patterns, in-depth
pipeline analysis, and deal analysis.
The
CRC therapeutics market in the eight major markets is expected to grow
at a Compound Annual Growth Rate (CAGR) of 1.8% to $9.4 billion by 2020.
The US had the largest market share in 2013, equivalent to a global
share of 44.1%, followed by Japan and Germany with 14.7% and 11.9%
respectively. Spain had the lowest market share of the leading eight at
4.1%. All markets covered in the report are expected to witness a slower
growth rate than Japan, which will grow at a CAGR of 5%. However, this
moderate growth will be stymied by the expected uptake of lower-priced
biosimilar versions of bevacizumab and cetuximab due to the expiration
of the patents of Avastin and Erbitux in the latter half of the forecast
period. Also expected is the launch of generic versions of
capecitabine, which will also affect the market.
However, this will be
offset by the launch of premium-priced emerging therapies. Stivarga is
expected to be one of the biggest drivers of growth in the CRC market,
primarily due to its expected line extension in the first-line
metastatic setting as a maintenance treatment for patients with resected
liver metastases. The launch of Lonsurf (TAS-102), approved in Japan in
2014, in the third- and fourth-line settings will further increase the
pharmacological treatment rates in these lines, which will give patients
a more tolerable alternative to Stivarga. The moderate uptake of other
late-stage pipeline products, panitumumab and Xilonix, following their
expected approval, is expected to drive additional growth within this
market.
Download Sample copy of this Report at :http://www.marketresearchreports.biz/sample/sample/242389
The
CRC pipeline is highly robust, with potential drug candidates across
various Phases of clinical development. With nearly 400 active pipeline
molecules, the majority of the investigational drug candidates are being
evaluated for the treatment of CRC in advanced stages, either as
first-line or second-line therapies. The current investigational
pipeline candidates include new combination therapies and targeted
therapies, as well as promising immunotherapies and chemotherapy drug
candidates. As well as these active progressing pipeline molecules, the
pipeline also includes nearly 180 molecules that are either inactive or
discontinued.
Scope
The
report analyzes treatment usage patterns, market characterization, the
pipeline, and key licensing and co-development deals in the eight major
markets: the US, the UK, France, Germany, Spain, Italy, Japan and
Canada. It includes:
- A brief introduction to CRC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
- In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
- A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
- Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
- Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006
Reasons To Buy
The report will enhance your decision-making capability by allowing you to:
- Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
- Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
- Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
- Accelerate and strengthen your market position by identifying key companies for strategic partnerships
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time
and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports,
custom research, subscription access and consulting services. We serve
all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
No comments:
Post a Comment